Jacobs Levy Equity Management’s Metagenomi Therapeutics MGX Stock Holding History

Jacobs Levy Equity Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$190K	Sell	160,000 -222,153	-58%	-$297K	﹤0.01%	912
2026 Q1	$512K	Buy	+382,153	New	+$594K	﹤0.01%	825
2025 Q4	–	Sell	-34,169	Closed	-$81K	–	1075
2025 Q3	$81K	Hold	34,169	–	–	﹤0.01%	944
2025 Q2	$50.6K	Sell	34,169 -32,013	-48%	-$50.1K	﹤0.01%	1016
2025 Q1	$90K	Hold	66,182	–	–	﹤0.01%	1049
2024 Q4	$239K	Sell	66,182 -70,442	-52%	-$170K	﹤0.01%	888
2024 Q3	$296K	Buy	136,624 +92,468	+209%	+$321K	﹤0.01%	886
2024 Q2	$180K	Buy	+44,156	New	+$303K	﹤0.01%	924

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jacobs Levy Equity Management's MGX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Metagenomi Therapeutics (MGX) stake by 58% in Q2 2026, selling an estimated $297K and leaving 160,000 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Jacobs Levy Equity Management first reported a position in MGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $512K in Q1 2026. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Jacobs Levy Equity Management held 160,000 shares of Metagenomi Therapeutics worth $190K as of Q2 2026.
Jacobs Levy Equity Management sold 222,153 Metagenomi Therapeutics shares in Q2 2026, an estimated $297K.
Metagenomi Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #912 holding.
Jacobs Levy Equity Management first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 8 quarters since.
Jacobs Levy Equity Management's Metagenomi Therapeutics position peaked at $512K in Q1 2026.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.